Market leadership Epocrates is the leading medical app among US physicians with over 1 million clinicians relying on its drug monographs, interaction checks, medical calculators and other point‑of‑care tools, signaling strong enterprise credibility and high engagement potential for new product or expanded data offerings.

Strategic partnership Recent collaboration with DeepIntent for programmatic Point‑of‑Care advertising suggests a channel opportunity to extend Epocrates’ reach to advertisers and pharma brands seeking targeted clinician access, enabling co‑marketing or data‑driven ad solutions.

Expansion signals Historical mobile tool launches such as Bugs + Drugs and the COVID‑19 tool indicate a pattern of rapid feature expansion to address evolving clinical needs, creating opportunities for upsell of advanced decision support modules, new databases, or location‑based analytics for health systems.

Tech and data stack With a tech ecosystem including Salesforce, New Relic and OneTrust, Epocrates demonstrates enterprise‑grade data handling, security and performance monitoring, pointing to potential sales opportunities around API access, data monetization partnerships and compliance‑forward product integrations.

Financial and scale Revenue in the range of 50 to 100 million with 201–500 employees positions Epocrates as a scalable mover in clinical decision support, suggesting potential cross‑sell of premium modules, enterprise licensing, and international expansion discussions with mid‑market health networks and group purchasing organizations.